X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10088) 10088
Book Review (1756) 1756
Publication (939) 939
Book Chapter (30) 30
Conference Proceeding (29) 29
Book / eBook (7) 7
Dissertation (6) 6
Magazine Article (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9100) 9100
humans (8002) 8002
sirolimus - therapeutic use (4693) 4693
male (4317) 4317
female (4006) 4006
immunosuppressive agents - therapeutic use (3053) 3053
sirolimus (2983) 2983
rapamycin (2907) 2907
animals (2902) 2902
middle aged (2824) 2824
sirolimus - analogs & derivatives (2536) 2536
transplantation (2408) 2408
sirolimus - pharmacology (2325) 2325
treatment outcome (2124) 2124
everolimus (2056) 2056
adult (1924) 1924
sirolimus - administration & dosage (1921) 1921
aged (1902) 1902
surgery (1900) 1900
oncology (1486) 1486
immunology (1424) 1424
mice (1346) 1346
sirolimus - adverse effects (1196) 1196
cardiac & cardiovascular systems (1152) 1152
mammalian target (1133) 1133
mtor (1112) 1112
cancer (1110) 1110
tor serine-threonine kinases - antagonists & inhibitors (1086) 1086
time factors (1005) 1005
immunosuppressive agents - adverse effects (993) 993
stents (986) 986
pharmacology & pharmacy (973) 973
cyclosporine (934) 934
abridged index medicus (923) 923
drug-eluting stents (896) 896
follow-up studies (865) 865
analysis (863) 863
therapy (856) 856
antineoplastic agents - therapeutic use (815) 815
tor serine-threonine kinases - metabolism (815) 815
immunosuppression (808) 808
care and treatment (804) 804
drug therapy, combination (798) 798
kidney transplantation (796) 796
tacrolimus (761) 761
retrospective studies (736) 736
risk factors (725) 725
immunosuppressive agents - pharmacology (723) 723
immunosuppressive agents - administration & dosage (718) 718
graft rejection - prevention & control (717) 717
calcineurin inhibitors (711) 711
signal transduction - drug effects (711) 711
rats (691) 691
research (687) 687
cyclosporine - therapeutic use (651) 651
cell line, tumor (646) 646
tor serine-threonine kinases (630) 630
recipients (622) 622
health aspects (616) 616
stent (599) 599
prospective studies (588) 588
article (587) 587
kidney transplantation - immunology (583) 583
cell proliferation - drug effects (580) 580
restenosis (562) 562
mycophenolate-mofetil (552) 552
tacrolimus - therapeutic use (549) 549
drug therapy (541) 541
efficacy (533) 533
kidneys (530) 530
disease models, animal (526) 526
apoptosis (525) 525
cell biology (525) 525
medicine & public health (523) 523
signal transduction (522) 522
dose-response relationship, drug (518) 518
mycophenolic acid - analogs & derivatives (505) 505
proteins (505) 505
inhibition (493) 493
antineoplastic combined chemotherapy protocols - therapeutic use (490) 490
expression (488) 488
thrombosis (482) 482
coronary angiography (481) 481
urology & nephrology (480) 480
implantation (476) 476
mycophenolic acid - therapeutic use (468) 468
trial (468) 468
immunosuppressive agents (461) 461
survival (457) 457
adolescent (456) 456
activation (449) 449
phosphorylation (443) 443
hematology (434) 434
kidney neoplasms - drug therapy (432) 432
tumors (429) 429
immunotherapy (427) 427
autophagy (425) 425
sirolimus - pharmacokinetics (415) 415
carcinoma, renal cell - drug therapy (414) 414
pathway (413) 413
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9794) 9794
French (88) 88
Chinese (54) 54
German (50) 50
Spanish (42) 42
Japanese (29) 29
Russian (16) 16
Italian (12) 12
Hungarian (10) 10
Czech (7) 7
Polish (7) 7
Portuguese (5) 5
Dutch (4) 4
Finnish (2) 2
Lithuanian (2) 2
Turkish (2) 2
Danish (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2013, Volume 71, Issue 9, pp. 1532 - 1540
Purpose To investigate the efficacy and safety of zoledronic acid (ZA) combined with targeted therapy (TT). Materials and Methods A retrospective study was... 
Surgery | SURVIVAL | PROSTATE | ADHESION | BISPHOSPHONATES | CANCER-PATIENTS | NECROSIS | DENTISTRY, ORAL SURGERY & MEDICINE | SKELETAL-RELATED EVENTS | SUNITINIB | BREAST | PROGRESSION | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Interleukin-2 - therapeutic use | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Angiogenesis Inhibitors - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Radiography, Panoramic | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Bone Density Conservation Agents - adverse effects | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Fractures, Spontaneous - etiology | Survival Rate | Spinal Cord Compression - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Cohort Studies | Care and treatment | Trade and professional associations | Metastasis | Index Medicus | Abridged Index Medicus | Dentistry
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 10/2015, Volume 15, Issue 10, pp. 2655 - 2664
This study shows that in de novo kidney transplant recipients receiving no CMV pharmacological prophylaxis, the use of everolimus and low‐dose tacrolimus is... 
nephrology | immunosuppression | Immune modulation | kidney transplantation | SURGERY | PROPHYLAXIS | MANAGEMENT | THERAPY | MINIMIZATION | RAPAMYCIN INHIBITORS | IMMUNOSUPPRESSION | DISEASE | CALCINEURIN INHIBITOR | PREVENTION | MTOR | TRANSPLANTATION | Prospective Studies | Cytomegalovirus Infections - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Postoperative Complications - prevention & control | Antibodies, Monoclonal - therapeutic use | Male | Cytomegalovirus Infections - immunology | Everolimus - administration & dosage | Postoperative Complications - immunology | Incidence | Dose-Response Relationship, Drug | Cytomegalovirus Infections - prevention & control | Antilymphocyte Serum - therapeutic use | Adult | Everolimus - therapeutic use | Female | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Sirolimus - therapeutic use | Graft Rejection - prevention & control | Treatment Outcome | Kidney Transplantation | Postoperative Complications - epidemiology | Tacrolimus - therapeutic use | Mycophenolic Acid - therapeutic use | Prednisone - therapeutic use | Kidneys | Tacrolimus | Organ transplant recipients | Cytomegalovirus infections | Transplantation | Angiogenesis inhibitors | Health aspects | Cytomegalovirus | Mycophenolic acid | Wound healing | Prophylaxis | Infections | Prednisone | Glomerular filtration rate | Graft rejection | Thymocytes | Motivation | Globulins | Antilymphocyte serum | Proteinuria | Kidney transplantation | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Circulation, ISSN 0009-7322, 04/2012, Volume 125, Issue 16, pp. 2015 - 2026
Journal Article
Journal Article
Autophagy, ISSN 1554-8627, 08/2014, Volume 10, Issue 8, pp. 1391 - 1402
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2007, Volume 356, Issue 15, pp. 1503 - 1516
Journal Article